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Summary
Background. Relaxin is a peptide hormone that exerts specific effects on cardiovascular sys-
tem and human brain, leading to the hypothesis that this hormone may play a protective role 
against CVD and integration and modulation of behavioral activation.
We aimed to demonstrate the efficacy of Relaxin on functional recovery of post-stroke patients.
Methods. Patients admitted within a Rehabilitation Unit suffering from stroke have been evalu-
ated. Patients have been randomized to RLX (40 mcg/d) plus rehabilitation vs a control group 
that underwent only rehabilitation. A preliminary analysis of 36 patients at 20 and 40 days was 
made using the mRS for global function, the Functional Independent Measure (FIM) for daily 
activity and Trail Making Test (TMT) for cognitive function. 
Results. Eighteen patients (age 72 (64-79), M 56%) randomized to RLX plus rehabilitation were 
compared to 18 patients (age 68 (64-78), M 50%) that underwent only rehabilitation. There was 
no difference between the two groups in terms of risk factors, stroke syndromes and etiology. 
At admission the two groups showed the same characteristics in terms of functional aspects 
(mRS, FIM; p ns) and cognitive function (TMT; p ns). After 20 days (T1) the treatment group 
(RLX+rehabilitation) showed no differences between the two groups (FIM 78 vs 69; p ns), while 
after 40 days (T2) patients treated with RLX+R showed an excellent recovery (FIM 96 vs 75; 
p0.001). In terms of cognitive function patients RLX+R revealed a better performance at T1 ( 
TMT 3.5 vs 2; p 0.002) and still better at T2 (TMT 4 vs 2; p 0.001). These results have been 
confirmed in terms of global function both at T1 (mRS 2.5 vs 3; p0.001) and T2 (mRS 2 vs 3; p 
<0.001) .
Conclusion. Relaxin showed in this analysis a positive effects on stroke patient’s recovery, thus 
offering the broad therapeutic potential role of RLX as new drug in post-stroke patients.
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Relaxin (RLX) belongs to the relaxin hormone family, which in humans includes 
3 RLX molecules and 4 insulin-like peptides(1). Formerly known for its effects on 
reproduction and pregnancy(2), is actually proposed as a pleiotropic hormone for 
his multiple actions on numerous organs and systems, caused mainly by its proper-
ty of inducing nitric oxide(NO) synthesis and release(3). It has been deeply studied 
on cardiovascular system where produces microvessels dilation(4), coronary blood 
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flow increase (3), inhibition of platelet aggregation and, in ischemic tissues, neo-an-
giogenesys (5) and leucocytes migration(6). Those actions permit that RLX potently 
counteracts myocardial ischemic damages in experimental heart infarction (7). Recent 
studies on rat demonstated that RLX administration reduced the extension of the 
damaged tissue following experimental brain ischemia (8). 
Furthermore RLX may also elicites direct actions on the central nervous system. In 
fact brain has an high concentration of RLX receptors (9) and an isoform of RLX has 
been discovered in the brain, where it has been postulated to act locally as a neurotr-
asmitter (10); furthermore RLX acting on circumventricular organs, stimulates water 
drinking and vasopressing release and appears to be involved in the regulation of 
behavioural processes (10) .
 Based on the RLX properties on the vascular system and the brain functions, we 
aimed to evaluate the effect of oral administration of Relaxin in improving recovery 
of post-stroke patients during an admission in a rehabilitation Unit and compare the 
effects with patients undergoing only the rehabilitation setting.
Patients and Methods
Were recruited consecutive post-stroke patients admitted to our Clinical.
Eligibility criteria included: 1) clinical diagnosis of ischemic stroke within the pre-
vious three weeks 2) 18-85 years of age, 3) mRS at admission £3, 4) neither life-threat-
ening major pathological conditions nor alcohol habit, 5) neither serious language 
disturbance nor poor compliance.
Eligible patients were randomly assigned to receive either RLX (40 mcg /die) plus 
rehabilitation (RLX+R) or rehabilitation (R). 
To assess the stroke recovery we used the mRS for global function (11), the Function-
al Independent Measure (FIM) for daily activity( 12), and the Trail Making Test (TMT) ( 
13) for cognitive function, respectively at admission (T0), after 20 (T1) and 40 days (T2). 
We used purified RLX ,extracted by porcine corpora lutea and prepared in a gas-
tro-protected oral form. The trial was approved by the local ethical Committee. 
Patients or legally accepted surrogates provided informed consent prior to study entry.
Statistical Analysis
We performed the statistical analysis with the SPSS package for windows, and 
confidence interval analysis softwares. We used median values, interquartile ranges 
(IQR), and percentages (%). We compared groups for categorical variables, with the 
Chi Square test with Yate’s correction or Fisher exact test when appropriate, and for 
continuous variables with the Mann and Withney U test. 
Results
Eighteen patients (age 72 (64-79), M 56%) randomized to RLX +R were compared 
to 18 patients (age 68 (64-78), M 50%) that underwent only R. There was no differ-
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ence between the two groups in terms of risk factors, stroke syndromes and etiology. 
At admission the two groups showed the same characteristics in terms of function-
al aspects (mRS, FIM; p ns) and cognitive function (TMT; p ns). After 20 days (T1) 
the treatment group (RLX+R) showed no differences between the two groups (FIM 78 
vs 69; p ns), while after 40 days (T2) patients treated with RLX+R showed an excel-
lent recovery (FIM 96 vs 75; p0.001). In terms of cognitive function patients RLX+R 
revealed a better performance at T1 ( TMT 3.5 vs 2; p 0.002) and still better at T2 
(TMT 4 vs 2; p 0.001). These results have been confirmed in terms of global function 
both at T1 (mRS 2.5 vs 3; p0.001) and T2 (mRS 2 vs 3; p <0.001) .
The treatment has been well accepted by the patients with good compliance; no 
negative side effects were registered.
Discussion
This is the first human study to test the effects of RLX on Stroke patients recovery. 
After 40 days-follow-up we noticed a positive effects of RLX+R on cognitive func-
tions, motor functions and global recovery respect R group in post-stroke patients. 
The effects on cognitive functions is clear after 20 days and improved still after 40 
days of administration. A positive trend can be noticed for functional activities (FIM) 
during the first period and become clear after 40 days. The positive effects are con-
firmed in terms of global function with an evident improvement of mRS score during 
the all observational time. No adverse side effects have been registered. 
Evidences of our results and our studies on experimental ischemic diseases con-
firm that RLX must be considered as a novel therapeutic tool in human ischemic dis-
eases, not only as a protective agent, but also as an efficacious therapeutic possibility 
to ameliorate and reduce the symptoms produced by the ischemic event. In fact the 
positive effects we described were found during the patients recovery, confirming our 
observation in rat and pig experimental myocardial infarction that RLX counteracts or 
reduces ischemic damages not only when given before but also after the occurrence 
of ischemia (14). Furthermore in a recent Pre-Relax AHF study, relaxin was associated 
with favourable relief of dyspnoea and other clinical outcomes, with acceptable safety, 
when given to patients with acute heart failure (15). It is possible that other actions 
of RLX, specific for the Central Nervous System and different from the vascular ones, 
may contributed to the clinical ameliorations described. Experimental evidence sug-
gests that relaxin-3, a recently discovered member of the insulin superfamily, is an 
orexigenic hypothalamic neuropeptide(8). It is expressed at greatest levels in the cen-
tral nervous system, and expression is localized to a distinct area called the nucleus 
incertus, situated in the caudoventral region of the pontine periventricular gray (9). 
Anatomical studies suggest that this nucleus is involved in a midbrain behavior con-
trol network that influences circuits regulating locomotion, attention, and learning 
processes(10) and that responds to stress-related neuroendocrine signals. 
RLX has some other major advantages: it is a natural hormone targeting endog-
enous receptor/signal tranduction mechanisms; it has similar tertiary structure in 
many animal species and in humans, thus being poorly immunogenic. This high-
lights that, regardless the dose and delivery route, adverse side effects are indeed 
rare(14).
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Table 1. Comparisons of the baseline characteristics between patients enrolled in either treatment. Data 
provided are number of patients (%) unless specified. *median (interquartile range). TACS: total anterior cer-
ebral stroke, PACS: partial anterior cerebral stroke, POCS. posterior cerebral stroke and LACS: lacunar stroke 
syndrome. Statistics were performed with the Chi Square test (with Yates’ correction or Fisher’s exact test 






Age (years)* 72 (64-79) 68 (64-78) ns
Male gender 10 (56) 9 (50) ns
Medical history
Arterial hypertension 14 (78) 9 (22) ns
Diabetes mellitus 9 (50) 8 (44) ns
Hypercholesterolemia 7 (39) 7 (39) ns
Previous transient ischemic attack 6 (33) 2 (11) ns
Prior ischemic heart disease 6 (33) 7 (39) ns
Atrial fibrillation 4 (22) 4 (22) ns
Cigarette smoking (currently) 8 (44) 3 (17) ns
Stroke syndrome
TACS 3 (17) 4 (22) ns
PACS 7 (38) 6 (33) ns
POCS 3 (17) 3 (17) ns
 LACS 5 (28) 5 (28) ns
Presumed etiology 
Small-artery occlusion 6 (33) 6 (33) ns
Large-vessel atherosclerosis 6 (33) 5 (28) ns
Cardioembolism 6 (33) 7 (39) ns
Other determined caused 0 (0) 0 (0) ns
Undetermined causes 0 (0) 0 (0) ns
In conclusion, our first analysis, confirms that RLX is a safety natural hormone as 
resulted in previos human studies and suggests his action on some brain processes, 
improving the motor and cognitive functions in post-stroke patients, when used in 
concomitant with physical exercise.
Many other studies need to be done to extend our results, expecially regarding 
different doses and lenght of treatment and also focusing on the best bio-availability 
upon oral administration ;for the near future we may hope that pharmaceutical stud-
ies may increase the possibility of availability of RLX for theapeutical applications 
also searching for the optimal RLX analogues easier to obtain and able to compete 
with the authentic hormone to its receptors.
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Table 2. Comparisons of the outcome measures between patients enrolled in either treatment. *median 
(interquartile range). Comparison of mRS: modified Rankin Scale. FIM: Functional Indipendence Measure. 
TMT: Trail Making Test. Statistics were performed with the Mann and Withney U test. P values < 0.05 were 






Baseline* 3 (2-4) 3.5 (3-4)  ns
T1* 2.5 (2-3) 3 (3-3)  0.001
T2* 2 (1.75-2) 3 (2-3)  <0.001
FIM
Baseline* 53 (45-61) 59 (45-65)  ns
T1* 78 (70-85) 69 (54-81)  ns
T2* 96 (87-100) 75 (65-89)  0.001
TMT
Baseline* 2.5 (1-3) 1.5 (1-3)  ns
T1* 3.5 (2.75-4) 2 (1-3)  0.002
T2* 4 (3-4) 2 (1-3)  0.001
Figure 1. Comparisons of the outcome measures between patients enrolled in either treatment. Median 
(Standard Deviation). Comparison of mRs: modified Rankin Scale. R: rehabilitation
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